Journal
CLINICAL MICROBIOLOGY REVIEWS
Volume 34, Issue 1, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CMR.00043-19
Keywords
cytomegalovirus; antiviral agents; clinical trials; diagnostics; immune monitoring; immunocompromised hosts; transplant infectious diseases; transplantation; vaccines
Categories
Funding
- National Institute of Allergy and Infectious Diseases, National Institutes of Health [HHSN272201100041C, K24HL093294, HHSN272201600015C]
- Chimerix Inc.
- Gilead Sciences
- Takeda
- Merck
- Astellas
Ask authors/readers for more resources
Individuals with compromised immune systems are at the highest risk for complications from CMV infection, including those living with HIV/AIDS, transplant recipients, and fetuses. Despite significant progress in prevention, diagnostics, and treatment, there are challenges in optimal control of CMV infection and disease in transplant settings.
Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new approaches and remaining challenges to the optimal control of CMV infection and disease in transplant settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available